-
Connect Biopharma Shifts Focus to US, Plans Further Reduction in China Workforce
•
Connect Biopharma Holdings Ltd (NASDAQ: CNTB), a Sino-US biotechnology company that initially operated in Suzhou before relocating its headquarters to the US, has released its financial report for the first half of 2024. The report highlights the company’s strategic decision to retract its presence in the Chinese market as it…
-
Simcere Pharmaceutical Secures Rights to Develop Rademikibart in China
•
China’s Simcere Pharmaceutical Co., Ltd (HKG: 2096) has entered into an agreement to acquire the rights to develop the anti-inflammatory monoclonal antibody rademikibart from US-based Connect Biopharma Holdings Ltd (NASDAQ: CNTB). The deal, negotiated with Connect Bio’s China-based subsidiaries, Connect Biopharma Hong Kong Ltd and Suzhou Connect Biopharma Co., Ltd,…
